News - Eisai


Current filters:


Popular Filters

90 to 113 of 113 results

Eisai re-submits perampanel NDA; FDA accepts Gilead’s Quad


Japanese drug major Eisai (TYO: 4523) says that it has re-submitted the New Drug Application (NDA) for…

Anti-viralsEisaiGilead SciencesNeurologicalperampanelPharmaceuticalQuadRegulation

Eisai in deal with Novartis to co-promote COPD drugs in Japan


Japanese drugmaker Eisai (TYO: 4523) has entered into a Japan co-promotion agreement with the local subsidiary…

Asia-PacificEisaiLicensingMarkets & MarketingNovartisOnbrezPharmaceuticalRespiratory and Pulmonary

UK’s NICE rejects Eisai’s Halaven for advanced breast cancer


In a second negative from the UK’s National Institute for Health and Clinical Excellence, in final…


Mixed half-year results from Astellas, Eisai and Santen


Compared with some of its peers which reported first-half fiscal year 2011/12 (ended September 30) financial…

Astellas PharmaEisaiFinancialPharmaceuticalSanten Pharmaceuticals

Eisai wins patent extension in Japan for blockbuster Alzheimer’s drug Aricept


Japanese drug major Eisai (TYO: 4523) says that the Supreme Court of Japan has turned down a petition…


Eisai updates on epilepsy drugs Zonegran, Zebinix and perampanel at IEC


Japanese drug major Eisai (TYO: 4523) presented new data at the International Epilepsy Congress taking…


Abbott and Eisai launch of PDER drug Lipacreon in Japan


Following regulatory approval earlier this year (The Pharma Letter April 27), the Japanese subsidiary…

Abbott LaboratoriesAsia-PacificEisaiGastro-intestinalsLipacreonMarkets & MarketingPharmaceutical

Eisai sets up subsidiary in Mexico to expand Latin American presence


Following in the path of other Japanese drug majors, Eisai (TYO: 4523), through its US unit, has established…

EisaiMarkets & MarketingPharmaceuticalSouth America

Arena and Eisai release data on obesity drug candidate lorcaserin to be used in CRL response


USA-based Arena Pharmaceuticals (Nasdaq: ARNA) and Japanese partner Eisai (TYO: 4523) announced the completion…

Arena PharmaceuticalsEisailorcaserinMetabolicsPharmaceuticalResearch

Eisai epilepsy drug delayed by US FDA, but Zonegran use extension filing accepted in EU


There was disappointment for Japanese drug major Eisai (TYO: 4523) last week when the US Food and Drug…

EisaiEuropeNeurologicalNorth AmericaperampanelPharmaceuticalRegulationZonegran

Daiichi Sankyo debuts Lixiana in Japan for VTE prevention after orthopedic surgery


Building on its cardiovascular portfolio, Japanese drug major Daiichi Sankyo (TYO: 4568) has launched…

Asia-PacificCardio-vascularEisaiLixianaMarkets & MarketingPharmaceutical

Negative draft guidance from UK’s NICE for Eisai’s Halaven


In yet another negative opinion for breast cancer use on the UK’s National Health Service, UK drugs…


Eisai gets Chinese rights for Orion’s Fareston and Eldepryl; FDA accepts Dacogen sNDA


Japanese drug major Eisai (TYO: 4523) has entered into a comprehensive marketing agreement with Finland’s…

DacogenEisaiEldeprylFarestonOrion Pharma

Eisai to file Zonegran as first-line epilepsy therapy in Europe on good trial results


Based on the positive results of a late-stage clinical trial, Japanese drug major Eisai’s (TYO:…


Pfizer Japan unveils positive top-line Ph III results for Lyrica in fibromyalgia


The Japanese subsidiary of global drugs behemoth Pfizer (NYSE: PFE) has released top-line results from…


Public Citizen says US FDA should immediately pull Eisai and Pfizer’s high-dose Aricept from market


US consumer watchdog Public Citizen has called for higher doses of Aricept (donepezil), marketed by originator…

AriceptEisaiNeurologicalNorth AmericaPfizerPharmaceuticalRegulation

Eisai gets Swiss approval for Halaven


Japanese drug major Eisai (TYO: 4532), says that its Halaven(eribulin) has been approved for use in…


US FDA not ready to approve Eisai Aricept Patch; Lipacreon and Halaven OKed in Japan


Japanese drug major Eisai (TYO: 4523) says that the US Food and Drug Administration has issued a Complete…

AriceptAsia-PacificEisaiHalavenLipacreonNeurologicalNorth AmericaOncologyPfizerPharmaceuticalRegulation

90 to 113 of 113 results

Back to top